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3 Summary 
1  INTRODUCTION AND BACKGROUND 
This 1996 report is the third report to be presented by the Commission. It reviews 
the situation at October 1996, i.e. just before the date by which the Commission 
had to present draft measures postponing the date for the ban on animal testing in 
cases where alternative methods of testing have not been scientifically validated 
as offering an equivalent level of protection for the consumer, taking into account 
OECD guidelines. It belongs in the context of the sixth amendment to  the basic 
Cosmetic Products Directive adopted by the Council on 14 June  1993  (Directive 
93/35/EEC), which provides for the banning of cosmetic products \Vhich contain 
ingredients or combinations of  ingredients tested on animals as of 1 January 1  998 
unless  alternative  methods  are  not  available  by  this  date,  in  which  case  the 
Commission  must  present  draft  measures  to  postpone  the  ban.  The  sixth 
amendment  also  provides  that  the  Commission  shall  present  annual  progress 
reports to the EP and Council. 
The 1996 report consists of  two parts. The first, more general part: 
describes the objectives and constraints which have to be addressed, 
summarises the existing and expected results, 
specifies the conclusions drawn by the Commission from these objectives, 
constraints  and  results  in  preparing  its  draft  proposal  for  a  Directive 
postponing the deadline of 1 January 1998. 
The second part of  the report is more scientific. It explains: 
the· initiatives  taken  in  1996  by  the  various  parties  involved  m  the 
research, validation and legal acceptance of  alternative methods. 
the difficulties involved in obtaining statistics, 
the state of  progress in each individual domain. 
2  OBJECTIVES AND CONSTRAINTS 
· There are two key objectives - namely ensuring the safety of cosmetic products 
for human health and the elimination/reduction of  animal suffering. 
Cosmetic  products,  which  include  personal  hygiene  products,  are  used 
throughout  a  person's  life.  The  Cosmetic  Products  Directive  makes  it 
incumbent on manufacturers to ensure that cosmetic products are safe for 
human  health  and,  as  of 1 January 1997,  to  keep  a  safety  information dossier  which  will  be  accessible  to  the  monitoring  authorities.  The 
Cosmetic  Products  Directive  has  also  established  a  system  of lists  of 
substances  that  are  banned,  subject  to  restrictions,  or  authorised 
respectively. These lists are regularly adapted to technical progress, on the 
basis  of  an  opinion  delivered  by  the  Scientific  Committee  on 
Cosmetology, which takes into account the results of  tests. 
The  banning  of all  new  ingredients  would  not  make  tests  superfluous 
because the safety of ingredients must be regularly reexamined in the light 
of scientific progress. Neither can one outlaw all  innovation - a measure 
which would bankrupt numerous SMEs. 
The reduction and elimination of animal suffering is an ethical imperative. 
Although animal tests in the field of cosmetic products account for a mere 
0.03% of  all animal tests, they have been given priority. 
The report describes the work done in 1996 by the following parties: 
the Commission and notably ECV  AM, the European Centre for the 
Validation of Alternative  Methods,  a unit  of the  Joint  Research 
Centre; DG XI "Environment, Nuclear Safety and Civil Prqtection, 
which manages Directive 86/609 on the protection of animals used 
·for  scientific  and  experimental  pl,ll'poses;  DG XII  "Science, 
Research  and  Development",  in  funding  research  programmes; 
DG XXIV  "Consumer  Policy",  which  manages  the  Cosmetic 
Products Directive and the Scientific Committee on Cosmetology. 
the Scientific Committee on'Cosmetology; 
CO LIP A/the  European  Cosmetic,  · Toiletry  and  Perfumery 
Association; 
*  the OECD. 
However, the report emphasises that the development, validation and acceptance 
of alternative methods is a process which has proven more complex and arduous 
than  initially foreseen  and that,  as  in  all  scientific research,  it  is  impossible to 
guarantee a precise result by a given date. The report also stresses that the utmost 
prudence is called for as regards the use of human volunteers, who cannot serve 
as a substitute for animal experiments pure and simple. 
The constraints that have to be borne in mind are mainly: 
compliance with the rules of international trade, notably those of the WTO 
(World  Trade  Organisation).  The  point  is  that  any  measure  having  the 
effect of banning products from third countries on the grounds that these 
products  have  been tested  on animals  poses  problems  of compatibility 
with  the  rules  of international  trade.  It  would  appear  necessary  to 
investigate the subject in greater detail in the context of preparing an EP and  Council Directive which the  Commission intends to propose during 
the  coming  months,  designed  to  amend  the  basic  Cosmetic  Products 
Directive so as to address, in a legally appropriate text, the ban on animal 
testing by regulating in particular the question of  finished products. 
the  interests of the employment-generating  SMEs, which also  must be 
taken into account. Measures must be taken to ensure that they are trained 
and infonned. 
3  EXISTING AND EXPECTED RESULTS 
The results are summarised in the first part of  the report and described in greater 
detail in the second part. 
A  distinction  must  be  made  between  (a)  ingredients  and  combinations  of 
ingredients and (b) finished cosmetic products. 
As regards  test~ on ingredients/ combinations of  ingredients the report makes it 
clear that no  alternative method  offering an  equivalcirt degree of protection is 
available to date, or likely to be available by 1 January 1998. 
Methods which do not involve animal trials will however become progressively 
available in the  fields of percutaneous absorption and local risks to the eye and 
skin: photoirritation, eye irritation and skin irritation. 
However,  as  regards  tests  concerning  the  system  risks  - i.e.  risks  involving 
exposure of  the organism as a whole as opposed to local risks - there is no hope 
that animal trials can be replaced on schedule. However, the number of animals 
used is being steadily reduced. 
In general it will be possible to evaluate the safety of  the finished products after 
1 January 1998  without  recourse  to  animal  trials,  thanks  notably  to  existing 
knowledge on the safety of  the ingredients, and by methods not involving the use 
of animals, even if these methods are not liable to be the subject of an OECD 
guideline,  which  deals  exclusively  with  ingredients  and  combinations  of 
ingredients. However, in certain cases there may be a risk of  toxic effects. due for 
example to the interaction of  the ingredients or to the fact that skin penetration of 
the ingredients is facilitated by the vehicle used. In such cases tests on animals 
would remain necessary. 
' 4  CONCLUSIONS  DRAWN  BY  THE  COMMISSION  FROM  THESE 
OBJECTIVES, CONSTRAINTS AND RESULTS 
The  Commission's  draft  directive  designed  to·  postpone  the  deadline  of 
1 January 1998 takes into account the objectives, constraints and results described 
in the report. 
The  Commission  notes  that,  while  progress  has  been  made  in  research  into 
alternative test methods, notably in the fields of  percutaneous absorption and local 
risks to the eyes and skin, the fact remains that no alternative method has yet been 
scientifically  validated  and  accepted  andthat  the  OECD  has  not  yet  adopted 
pertinent guidelines on toxicity tests in the field of  alternative testing methods. 
The situation is unlikely to change before 1 January 1998. 
Hence  the  draft Directive proposes the postponement of the  date  mentioned in 
Article 4(1)(i) of Directive 761768/EEC, in compliance with the second sentence 
of that provision, until 30 June 2000, before which date it can be foreseen that no 
alternative testing method will have been adequately scientitically validated and 
accepted. 
It also  provides that before  1 January 2000 the  Commission shall present draft 
measures taking into account progress made by that date. 
The  Commission  also  wishes  to  promcte  research  into  and  the  validation  of 
alternative methods. 
As regards finished products, the Commission will take measures to promote the 
dissemination among SMEs of  methods not involving the use of  animals. 
The Commission has also initiated refltctions and intends, in the coming months, 
to  present a proposal  for  a European Parliament and  Council  Directive  on the 
amendment of  Article 4 (1) (i) to address, in a legally appropriate text, the ban on 
animal testing in respect of  finished cosmetic products - barring exceptional cases 
- as  of 1 January  1998,  in  order to  comply with the  requirements of Directive 
761768. 
This  proposal  for  a Directive should also  regulate  aspects  relating  to  products 
from  third countries and clarify certain concepts and references in the text that 
have given rise to questions. 
Since  the  Directive  will  be  based  on  Article  1  OOa,  this  Commission  proposal 
requires the approval of  the European Parliament and the Council. 
f PART I 
1996 Commission Report 
on the development, validation and legal acceptance of  alternative methods to animal 
experiments in the field of  cosmetics. 
A.  INTRODUCTION AND BACKGROUND 
The Commission has already presented two annual reports on 1994 and 1995 data 
concerning  progress  in  the  development,  validation  and  legal  acceptance  of 
alternative methods to animal experiments in the field of  cosmetics. 
This 1996 report reviews the scientific situation at October 1996. 
This  1996  report belongs in the  context of Directive 76/768/EEC  on cosmetic 
products, whose new Article 4 (1) (i),  introduced by Council Directive 93/35 of 
14 June 1993, provides that Member States shall ban the placing on the market of 
cosmetic products containing ingredients or combinatiol}.s of  ingredients tested on 
animals after 1 January 1998 in order to meet the requirements of  this Directive. 
However,  this  Article  specifies that  "if there  has been insufficient progress  in 
developing  satisfactory  methods  to  replace  animal testing,  and  in  particular in 
those  cases  where  alternative  methods  of  testing,  despite  all  reasonable 
endeavours, have not been scientifically validated as offering an equivalent level 
of  protection for the consumer, taking into account OECD toxicity test guidelines, 
the Commission, shall, by 1 January 1997, submit draft measures to postpone the 
date of implementation of this provision, for a sufficient period, and in any case 
for no less than two years, in accordance with the procedure laid down in Article 
10. Before submitting such measures, the Commission will consult the Scientific 
Committee on Cosmetology". 
This 1996 report comprises two parts. The first, more general part, describes the 
objectives and constraints that have to  be  addressed,  the  existing and expected 
results as regards ingredients and combinations of ingredients on the one hand 
and finished products on the other, and the conclusions drawn by the Commission 
from these objectives, constraints and results in preparing its draft proposal for a 
Directive to postpone the deadline of I January 1998. 
The second part of  the report is more scientific. It describes: 
the  initiatives  taken  in  1996  by  the  different  parties  involved  in  the 
development,  validation  and  legal  acceptance  of alternative  methods, 
specifying wherever possible the cost of  these initiatives 
the difficulties in obtaining statistics 
8 the state of  progress in each individual domain. 
B.  OBJECTIVES AND CONSTRAINTS 
Two principal objectives must be pursued and wherever possible reconciled in the 
field  of cosmetic products:  (a)  ensuring consumer safety  and (b)  reducing and, 
ideally, eliminating animal suffering. 
Moreover, various constraints must be borne in mind, the two primary ones being 
(a) the international arena and the need to  comply with WTO  rule~ and the rules 
of  free competition, and (b) the interests of firms, notably employment-generating 
small and medium-sized enterprises. 
1.  Consumer safety 
Consumer safety must remain paramount. Here it should be noted that the 
notion  of  "cosmetic  products"  encompasses  not  only  so-called 
"decorative"  products,  such as  lipstick  or  nail  varnish,  but  also  articles 
such as soap, shampoos, toothpaste which are used throughout a person's 
lifetime from early childhood on. It is essential that these products should 
not cause  harmful,  immediate  and  visible  effects,  such  as  irritation,  or 
long-term, latent effects such as risks of carcinogenicity or teratogenicity, 
etc. 
To ensure that cosmetic products are  safe  for  human health in  all  these 
respects, it is necessary to check not only the safety of  the finished product 
but also- and primarily- that of the ingredients used in its manufacture. 
It is  for  the  manufacturer  to  ensure  the  safety  of the  ingredients,  in 
compliance with Article 2 of the Cosmetic Products Directive, according 
to which cosmetic products must not be liable to cause damage to human 
health  when  they  are  applied  under  normal  conditions  of  use; 
manufacturers may also be held liable in the event of damages pursuant to 
Council  Directive  85/374/EEC  on  liability  for  defective  products. 
Pursuant to Council Directive 93/35/EEC of 14  June  1993  amending for 
the sixth time the  basic  Cosmetic  Products  Directive,  the  manufacturer 
must, as of 1 January 1995, keep certain information readily accessible to 
the competent authorities, including "assessment of the safety for  human 
health of  the finished product. To that end the manufacturer shall take into 
consideration  the  general  toxicological  profile  of the  ingredient,  its 
chemical structure and its level of  exposure." 
The  Cosmetic  Products  Directive  also  includes  a  series  of annexes 
featuring positive and negative lists of  substances. The general principle is 
that substances may be used freely, unless they are prohibited (Annex II), 
or subject to certain limitations and conditions (Annex Ill). There are three 
exceptions  to  this  general  principle:  the  only  colouring  agents, 
preservatives and UV filters authorised are those featuring in positive lists 
(Annexes IV, VI and VII). 
9 A  substance  can  only  be  included  in  these  lists,  which  are  adapted  to 
technical progress each year by a Commission Directive, if it has been the 
subject  of  an  opinion  delivered  by  the  Scientific  Committee  on 
Cosmetology concerning its toxicity for human health. This SCC opinion 
is prepared on the basis of all the existing scientific data and notably the 
test  results  furnished  by  industry,  which  may  concern  sensitisation, 
mutagenicity,  eye  mttation,  skin  irritation,  photoirritation. 
carcinogenicity, teratogenicity, and acute, subchronic and chronic toxicity, 
etc. 
While some 7 000 substances are  already used in cosmetic products and 
while for many cosmetic substances new tests are not generally required. 
it should however be stressed that such tests may sometimes be crucial in 
reevaluating,  on  the  basis  of  technical  progress  and  new  scientific 
knowledge,  certain substances which have  been  in  use  for  a  very  long 
time.  Hence each year the  SCC examines a series of banned  substances 
(numbering  approximately  400)  and  substances  subject  to  certain 
limitations and requirements (numbering approximately 50). 
It  must also  be  possible to  examine the risks associated with the  use  of 
these products in combination. Thus on safety grounds it is not possible to 
dispense entirely with animal trials, even in respect of substances already 
in  use.  Moreover,  in  the  cosmetic  products  sector  - as  in  all  other 
industrial  sectors  - it  would  be  neither  wise  nor  reasonable  to  bring 
innovation to  a standstill. Even if consumers were to  foresake their quite 
legitimate  hope  of obtaining  ever  better  products,  a  blanket  ban  on 
innovation by outlawing the use of new substances would certainly spell 
ruin  for  numerous  European  cosmetic  product  manufacturers,  mainly 
employment-generating SMEs. 
2.  The reduction and elimination of animal suffering 
Reduction  and,  where  possible,  elimination  of animal  suffering  is  an 
objective  that  deserves  the  closest  attention  and  in  respect  of which 
resources should be mobilised at all levels. 
This  objective  reflects  ethical  imperatives  concerning  respect  for  life. 
deep-seated public aspirations, and the wishes ofthe European Parliament. 
It finds  expression in  several  European instruments,  including  Directi\'e 
86/609/EEC on the protection of animals used for experimental and other 
scientific purposes and Directive 93/35/EEC (the sixth amendment to  the 
initial Cosmetic Products Directive). 
While consumer safety must be  assured, we  must also do  our utmost to 
ensure  that  animal  tests· are  replaced  by  alternative  tests  as  soon  as 
possible, provided these afford an equivalent level of  protection. Although 
animal trials in the cosmetics field account for a mere 0.03% of all animal 
tests  and  although all  chemical  substances already  have  to  be  tested  in 
10 order  to  provide  the  toxicity  data  required  under  Directive  92/32/.EEC, 
cosmetic products have been prioritised and there has been a major drive 
in  recent  years,  notably  since  the  adoption  of Directive  93/35/EEC,  to 
promote the  development of alternative  methods.  These  endeavours,  as 
well as progress !O date and the outlook for the future, are described in the 
1994  and  1995  annual reports  on  the  development,  validation and  legal 
acceptance of alternative  methods to  animal experiments  in the  field  of 
cosmetic products, already presented by the Commission to the EP and the 
Council. 
Notably, these reports describe the work done by a number of  players. Part 
II reviews the activities of  these players in 1996. 
In particular, these players are: 
ECVAM (the European Centre for the Validation of Alternative Methods), 
a unit of the Ispra Joint Research Centre,. which coordinates the validation 
of alternative methods at Community level, provides a forum for pooling 
information and works on the development, updating and management of 
a database and promotes dialogue between all interested parties. 
In  1996 ECVAM continued to  organise workshops of direct relevance to 
evaluating the safety of cosmetic products (based on e.g. data concerning 
alternative methods); it published in ATLA recommendations methods for 
·  assessing percutaneous absorption and  for  skin sensitisation testing,  and 
recommendations  on  the  application  of biostatistical  methods  to  the 
development  and  validation  of  alternative  toxicological  methods;  it 
subsidised and coordinated a study for testing UV filters listed in Annex 
VII  to  the  Cosmetic Products  Directive  (photoirritation);  it  conducted a 
formal  validation study  on four tests  of skin .corrosion,  and  maintained 
regular  contacts  with  the  OECD  and  began  a  number of prevalidation 
studies relevant to the cosmetics industry. 
The  Commission  (DG  XI  "Environment,  Nuclear  Safety  and  Civil 
Protection")  which manages  Directive  86/609/EEC  on the  protection of 
animals used for experimental or other scientific purposes, has continued 
to  follow  the  matter.  The Commission (DG XII "Science,  Resear& and 
Development")  has  also  subsidised  research  programmes  including  the 
development of  alternative methods. 
In  the  context of its  consumer policy,  the  Commission  (DG  XXIV)  has 
funded  research  and  participated  in  or organised  meetings  with  all  the 
partners involved and organised and followed up the meetings of  the sec. 
The  Scientific Committee on Cosmetology - whose mandate is  to  deliver 
s~ientific opinions to the Commission on ingredients listed in the Annexes 
to the Cosmetic Products Directive and on the applicability of alternative 
methods  validated  in  the  process  of evaluating  the  safety  of cosmetic 
products, and on the proposal for a Directive which the Commission must 
II present concerning the postponement of  the deadline for the ban on animal 
tests  in  cases  in  which  alternative  methods  will  not  be  available  by 
I January 1998 - met on numerous occasions in 1996 both in plenary and 
in  its  Alternative  Methods  Subcommittee,  sometimes  jointly  with  the 
European Industry. Besides the activities documented in Part II, the SCC 
adopted  in  1996  a  document  titled  "The  use  of alternatives  to  animal 
studies in the safety evaluation of cosmetic ingredients or combinations of 
ingredients". 
Finally, at OECD level, work has  been done on percutaneous absorption 
(meeting of  the national coordinators in Paris in September 1996). 
It is important to note that the development, validation and acceptance of 
alternative  methods cannot be  achieved overnight,  despite  all  the  effort 
that is being invested. 
Hence  the  validation  phases  - i.e.  the  complex  process  by  \vhich  the 
pertinence, reliability and reproducibility of a test developed for  routine 
application and legal acceptance is evaluated and monitored - have turned 
out to  be  more  numerous and complex than  initially  foreseen.  and  new 
phases have had to be incorporated. 
Moreover,  as  in  the  case  of all  scientific  research,  it  is  well-nigh 
impossible  to  guarantee  a  precise  result  by  a  given  date,  and  certain 
studies, which were thought to be on the verge of  completion - such as the 
EU/HO  study  on  alternatives  to  the  Draize  test  - turned  out  to  be 
disappointing as regards the predictability of  the risk. 
As regards alternative tests on human volunteers, for example in the tield 
of skin irritation, the utmost prudence is called for;  such tests should only 
be countenanced in the proven absence of  real risks. 
For all that, progress to date has already made it possible to  substantially 
reduce the  number of animals used and  to  mitigate their suffering,  - for 
example the use of three basic in  vitro mutagenicity tests will  obviously 
lead to further improvements in the future. 
3.  International aspects and the GATTffBT rules 
It  is  important  to  note  that  any  measure  that  leads  to  banning  the 
importation of  cosmetic products into the Community solely because these 
products  or their  ingredients  have  been  tested  on animals  ~might prove 
incompatible with the rules of international trade. The main restriction that 
public  international  law  imposes  on a  state  is  to  forbid  - except  in  the 
event of a specific rule to the contrary - any exercise of its power on the 
territory of  another state. 
12 Firstly, the WTO outlaws quantitative restrictions on imports (Art XI§l). 
Moreover,  Article  III§4  proscribes  all  discriminatory  measures  between 
like products, i.e.  in accordance with the accepted interpretation, products 
which do  not present physical differences.  Since the test method clearly 
has  nu physical  effect  on  the  product,  a  discrimination  based  on  this 
criterion might be held to fall foul of  Article 111§4. 
Finally, such a measure would not be easy to justify in the context of the 
general  exceptions  featured  in  Article  XX  of the  GATT  (and  more 
specifically subsection b),  which authorises - within the terms of Article 
XX  - measures  "necessary  to  protect  human,  animal  or  plant  life  or 
health". In the absence of case law in this area, it is not possible to  claim 
that protection of  animal welfare could be covered by the exception. 
Secondly,  as  regards  measures  designed  to  verify  compliance  with  the 
provisions  of the  Cosmetic  Products  Directive  - viz.  requirements  in 
regard to the protection of  human health- the provisions of  the Agreement 
on Technical Barriers to  Trade (TBT) and notably those of Article 6 must 
be borne in mind. Article 6 promotes the mutual recognition of conformity 
evaluation  procedures:  "Members  shall  ensure  that,  whenever  possible, 
that  results  of conformity  assessment procedures  in  other Members  are 
acc~pted, even when these procedures differ from their own, provided they 
are  satisfied that those procedures offer an assurance of conformity with 
applicable  technical  regulations  or  standards  equivalent  to  their  own 
procedures". 
Bearing  these  provisions  in  mind,  the  extraterritorial  application  of a 
Community measure banning animartrials could be considered as contrary 
to  the Community's international commitments. Moreover, Article 4(1 )(i) 
of this  Directive  specifies  that  the  ban  on· animal  testings  may  be 
postponed  if there  are  no  scientifically  validated  alternative  methods 
which  offer  the  consumer  an  equivalent degree  of protection.  Hence  it 
would be difficult to  deny the equivalence. from the viewpoint of human 
health protection, of animal tests with alternative test methods which are 
recognised as equivalent. 
It should be noted that the rationale behind the ban is not that animal tests 
do not permit correct assessment of compliance with the provisions of the 
Cosmetic  Products  Directive,  but  is  based  purely  on  ethical 
considerations. 
Thus  any  decision  on  the  use  of alternative  methods  could  also  be 
challenged  if it  were  adopted  on  a  unilateral  basis.  Moreover the  TBT 
Agreement  strongly  encourages  the  members of the  WTO  to  adopt  the 
pertinent  international  systems  for  assessment  of the  conformity  of a 
technical regulation (Article 9). However, Article 9 also specifies that this 
applies  only  to  the  extent  that  these  international  systems  are  in 
compliance with the provisions of Articles 5 and 6 of the selfsame TBT 
Agreement (Article 9§3). 
lJ Thus it  is  \;'ery  important to  remain at least within the framework of the 
Organisation  for  Economic  Cooperation  and  Development  (OECD),  to 
which moreover Directive 93/35 refers. 
Part II  of this report explains the role played by the OECD in regard to 
alternative  methods  in  the  different  domains  of the  safety  of cosmetic 
products and highlights the  close  links  which the  Commission has  also 
developed and maintains with the OECD in this specific field. 
The  Commission  is  reflecting  on  to  all  matters  relating  to  the  rules  of 
international trade  in  the context of preparing a proposal for  a European 
Parliament and Council Directive designed to amend the basic  Cosmetic 
Products  Directive to  address,  in  a  legally  appropriate  text,  the  ban on 
animal  testing,  notably  by  regulating  the  question  of finished  cosmetic 
products. 
4.  The interests of the SMEs 
Finally,  apart  from  consumer  safety  and  the  ethical  imperative  to 
reduce/eliminate  animal  suffering,  the  reasonable  interests  of  the 
cosmetics industry should also be taken into consideration, notably those 
of the  employment-generating  SMEs.  The  alternative  methods  to  be 
developed should be accessible to SMEs, even if  they do not have as many 
"in-house" toxicologists or the same amount of experience or field data, or 
the  internal  laboratories  and  financial  resources  available  to  the  large 
firms. 
In  this  context,  COLIPA  will  be  launching  a  major  drive  to  provide 
information  and  training,  in collaboration with  its  large  member  firms. 
Moreover,  it seems  that specialised laboratories are  springing up  whose 
services the  SMEs  will  be  able to  draw on for  alternative  trials,  as  and 
when such trials reach maturity. 
ECV AM could also be involved- possibly together with CO LIP A (Scaat) 
- in  training  SMEs  in  the  use  of alternative methods for  evaluating the 
safety of  cosmetic products. 
C.  EXISTING AND EXPECTED RESULTS 
1.  Tests on ingredients and combinations of ingredients 
It should be noted that, as shown in Part II, no alternative method offering 
consumers an equivalent degree of protection has yet been scientifically 
· validated and accepted by the regulatory authorities.  The OECD has not 
yet adopted pertinent guidelines for toxicity tests in the field of alternative 
testing methods for  ingredients and combinations of ingredients used in 
cosmetic products. 
14 However  progress  has  been  made  and  it  looks  as  though  alternative 
methods  will  progressively  become  available  in  the  various  safety 
domains pertaining to  percutaneous absorption and local risks to the eye 
and skin (photoirritation, eye irritation and skin irritation). 
However, these methods will not be validated and accepted by  1 January 
1998,  despite  the  high expectations that were  had,  mainly  in  regard  to 
percutanl!ous absorption and photoirritation. 
In regard  to  percutaneous  absorption and  local  risks,  the  situation  is  as 
follows: 
P  hotoirritation 
Photoirritation mainly concerns UV filters.  A special study to  follow the 
EU/COLIPA validation study is  scheduled for  1996. This is directed by 
Zebet,  and  subsidised  and  coordinated  by  ECV AM.  The  study  should 
make it possible to test UV filters in Annex VII to  the Cosmetic Products 
Directive  and  to  prepare  a  protocol  with  a  view  to  submitting  a  draft 
guideline to  the  OECD.  The  first  results of this  special study should be 
available by September 1997. 
Percutaneous absorption 
In  May  1996,  after  discussions  with  the  Commission,  the  industry 
presented the OECD with a draft new guideline on in vitro percutaneous 
absorption.  "In-house"  data  were  provided  to  support  this  doss~er.  A 
meeting of the  OECD  national  coordinators' group was held  in  Paris  in 
September 1996, but the rate of  progress toward acceptance slow. 
The Scientific Committee on  Cosmetology has  emphasised that the  test 
protocols  used  by  industry  had  not  yet  been  subjected  to  the  formal 
validation study and that the documentation was incomplete. However, the 
sec has  in  recent years  agreed to  use  in  vitro  percutaneous absorption 
data in evaluating the safety of several cosmetic ingredients. 
Eye irritation 
The  1995  Report  stressed  that  the  results  of the  validation  studies  of 
alternative methods to the Draize eye irritancy test had been disappointing 
(EU/Home Office study and COLIPA study). 
ECV AM  and CO LIP A held a meeting in December 1996  to  discuss the 
outcomes of  the EC/HO and COLIPA studies and plan new initiatives. 
15 Skin irritation 
ECV  AM  has  conducted  a  fonnal  validation  study  involving  four  skin 
corrosion tests, whose results are expected in 1997. 
The OECD is also planning a draft testing strategy to detennine the skin 
irritation potential of  chemical substances. 
The draft OECD strategy is to use a hierarc':lical approach by eliminating 
severe  skin  irritants  through  consideration  of the  structure  activity 
relations  (SAR's)  and  structure  property  relations  (SPR's)  and  data 
obtained  from  in  vitro  corrosion  tests,  before  considering  the  use  of 
conventional in vivo tests on rabbits or the use of  human volunteers. 
A  summary  of the  situation  regarding  local  risks  shows  that  progress 
should  proceed  apace  but  that  1 January  1998  is  too  early  for  the 
replacement of animal trials. However, as regards reducing the number of 
animals and their suffering, it may be noted that in practice in vitro tests 
are already used as screening or guideline tests and that certain data have 
already been provided to the sec. 
Skin sensitisation 
Research has led to a better understanding of  the scientific bases of 
skin sensitisation. 
ECV  AM is to take action in the light of the report of the ECV  AM 
workshop on this topic. 
Mutagenicity 
The  combination of three  basic  in vitro  tests  already  makes  it 
possible to demonstrate a mutagenic potential and this combination 
is  already  being  applied  in  evaluating  the  safety  of cosmetic 
ingredients. 
All rests on ingredients relating to systemic effects 
(Acute  toxicity,  subchronic  toxicity,  carcinogenicity, 
teratogenicity). Because they are linked to exposure of  the 
organism  as  a  whole,  there  is  no  hope  that  alternative 
methods to  replace  animal trials  will  be available  in the 
foreseeable future. 
However, the refinement of the methods used has already 
made it possible to reduce the number of  animals used and 
mitigate their suffering, and this trend is likely to continue. 
2.  Finished cosmetic products 
16 As regards finished cosmetic products, progress  to date suggests that it 
will generally be possible to evaluate their safety on the basis of  available 
knowledge on the toxicity of their ingredients and their physicochemical 
properties, using methods which do not involve the use of  animals, even if 
these methods are not liable to be the subject of  an OECD guideline which 
deals' dealing only with ingredients and combinations of  ingredients. 
Hence  it  will  only  be  necessary  to  resort  to  animal  testing  in  rare, 
exceptional cases, where there are grounds to fear that the toxic effects of 
the ingredients may be potentiated, notably when skin penetration of the 
ingredients is facilitated by the vehicle used or when such effects result 
from the interaction of the ingredients. The sec has emphasised this fact 
in its Guidelines on the use of  a}tematiye metbods to gnimaJ studies in tbe 
safetv evaluation of  cosmetic inifCdients or combinations of  inaredients ·of 
24 Mav 1996. 
Certain cosmetics  firms  already  very  o~en use  methods  which  do  not 
involve the use ofanimals to test their finished products. 
COLIPA (Ute  European Cosmetic, Toiletry and Perfumery Association) 
has announced that it could progressively establish a  voluntary ban on 
animal testing for finished cosmetic products - except in the exceptional 
cases referred to above- for the entire European cosmetics industry, and 
that it would be willing to organise technology transfer in this  respect. 
CO  LIP  A  has  also  said  that  it  could  ensure  the  widest  possible 
.dissemination of findings  in this area and promote training in European 
companies  and  laboratories;  this  training  could  be  coordinated . by the 
Commission's services. The Commission, in particular, will promote the 
dissemination  of methods  not  involving  animals  among  the  SMEs.  It 
could also endeavour to promote such measures .at international level. 
D.  CONCLUSIONS  DRAWN  BY  THE  COMMISSION  FROM  THESE  OBJECTIVES, 
CONSTRAINTS AND  RESULTS  IN  ITS  DRAFT  DIRECTIVE PARTIALLY POSTPONING 
THE  DEADLINE  OF  1 JANUARY  1998  AND  IN  ITS  REFLECTIONS  ON  THE 
PRESENTATION OF A PROPOSAL FOR A EUROPEAN PARLIAMENT A~D  COUNCIL 
DIRECTIVE AMENDING ARTICLE 4(1)(1) OF THE BASIC DIRECTIVE 
1  .  The draft Directive prepared by the Commission takes account of  the fact 
that,  while progress  has  been made  in research  into  alternative  test  methods, 
notably in the fields of percutaneous absorption and local risks to the eyes and 
skin,  the  fact  remains  that  no  alternative  method  has  yet  been  scientifically 
validated and accepted. The OECD has not yet adopted pertinent guidelines for 
toxicity tests in the field of  alternative testing methods. 
The situation is unlikely to change before 1 January 1998. 
17 Hence ~  drat DirectiYe prapna the postpaaeawf of 1bt date IMfttioaed in 
Article 4(  l )(i) of DUective 76i'76a~EE£, in compliiDCC wid! the lee aad  seftteDCe 
ofthat provision, for not less tba  two years. 
Cwready it is difticWt to predict ~Y  wt.n cer'  ia altea ~!Five methods for 
testiaa certlia iapedicnts or  oambi"''im of illpl  dima will  be  scientifically 
validated  However  as  it- is  llb!y- tblt llt•"dw- metboda  will  proaressively 
be.t.ome  avaiYIMe  ift  the  fiek! of pemKNl  I loll  absotjaiou, -~  eye  .....__u- ..1-:- ~  _ _...  ....:- ~~  ~  ......  ta-:~-- ..... _ 
au~  011W11  ~·~-.au au& ~  ~  \.~IS, ~,  Ull: 
Commissioa is miadNI of the- oO,jective  of Altide ot(l)(i), ·  tDe  draft Directive 
postpoDcs the "'-'~iDe  to a date by which it Clll be foleteell DO altemative method 
will have beeD ~Y  scieotifically validled llld accepted, viz. 30 June 2000. 
ft  also stiPulates tbat Wore I laaua'J 2000 die Ovnnissioo sball present draft 
measures takiDs into account pmpas  made by that date. 
F  inaUy,  in  the  CORtext  detcriDed  above,  aod  also  in  compliance  with  the 
provisions  of Article  130..:3)  of tbe  Treaty  aad Fourth  Raearch Framework 
P~  tbe  CommisSion  will  take  the  necessary  measures  to  promote 
research iuto tad the validation of altematM metbocb to Mime!  testing in the 
field  of ~  ad combiatioas  of  inpedieia  in  cosmecic  product 
formulations.  This  coulci tlb the  form  of a recital m  the draft pi'C)pO$ti  for  a. 
Directive. 
2.  ~  of a  preposal  for.· a  European  Parliament  mel  Council 
Directive amending Article 4( 1  Xi) of  the basic Directive  · · 
In the -coatext described in point Cl. above reiatiDa to the exiJtina and e."C.peCted 
resuks for finiJbed cosmetic  products, the Commission Us -~  reflections 
and'  intmds,  in  the  comiAa  moaths,  to  ptesent  a.  proposal  for  a  European 
Parliameat aDd Couneil Directive amendil:lg Article 4 (I)  (i) in order to address, in 
a leplly lppi'Cp'iate text, the hm  em aaimal testiq in. nprd  to fiaisbed cosmetic 
products - bmioc excepQaaal  CIICS - as  of L L  1998, ia order to  respect  the 
obliptioas of  Directive 761768. 
This proposal for a Directive should also regulate, in a legally appropriate text, 
aspects  concerning  products  from  third  countries,  and  clarify  the ·concept  of 
"fillisbed products".  . 
Since  the  Directive  will  be based  on  Artide  1  OOa.  tbd Commission  proposal 
requiles the approval of  the C®BCil and the European PlrliameDt. 
E.  CONCLUSIONS AND OUTLOOK 
1.  This report reviews the situation in tbe  immediate rwMlp to the date by 
which  the  Commissioa  must  present  a  draft  measure  postponing  the 
deadline  of 1 January  1998  in  areas  in  which  alternative  methods  for 
testing ingredients and combinations of inaredients wjll not  be  available 
by that date. 
18 2.  Two objectives must be pursued: consumer safety, which the Commission 
insists  must  not  be  compromised  in  any  way,  and  the 
elimination/reduction of  animal suffering. 
• 
• 
Banning all new ingredients would not remove the need for animal 
tests because the safety of ingredients has to be reexamined in the 
light  of  new  scientific  knowledge.  Moreover,  blocking  all 
irinovation could put firms  out of business and in  particular the 
employment-generating  SMEs.  It  should  be  noted  also  that 
cosmetic products include personal hygiene products, products for 
babies(  ... ) and not only so-called "decorative" products. 
Priority should be given to eliminating animal" suffering in the field 
of cosmetic products, even if tests  in this  domain account  for  a 
mere 0.03% of all tests. The Commission (ECV  AM, DG XI, XII, 
XXIV), the Scientific Committee on Cosmetology, the OECD and 
Industry continued to work to this end in 1996. 
However the validation process has turned out to be more complex than foreseen. 
In the  SCC's opinion the  utmost prudence  is  called for  as  regards  the  use  of 
human volunteers, who cannot simply serve as a stand-in for animal experiments. 
3.  Two constraints must also be borne in mind: 
a}  compliance  with  the  rules  of international  trade,  notably  those  of the 
WTO(World Trade Organisation). The point is that any measure having 
the  effect of banning products from  third countries on the grounds that 
these  products  have  been  tested  on  animals  poses  problems  of 
compatibility  with  the  rules  of  international  trade.  It  would  appear 
necessary  to  investigate  the  subject  in  greater  detail  in  the  context of 
preparing an EP and Council Directive which the Commission intends to 
propose during the coming months, Elesigned to amend the basic Cosmetic 
Products Directive so as to address, in a legally appropriate text, the ban 
on  animal  testing  by  regulating  in  particular  the  question  of finished · 
products. 
b)  the interests of  the SMEs, which must be trained and informed. 
4.  As regards the existing and expected results, a distinction must be made 
between ingredients/ combinations of  ingredients and finished products. 
a)  As  regards  ingredients  and  combinations  of  ingredients,  no 
alternative  method  will  be  ready  by  1 January  1998.  However, 
methods should progressively become available for percutaneous 
absorption,  photoirritation,  eye  irritation  skin  irritation  and  skin 
sensitivation. 
19 However, in the case of  tests concerning system risks, i.e. exposure 
of the  entire  organism,  there  is  no  hope  for  alternative  methods 
maturing in the foreseeable future. 
b)  In  general,  it should be possible to ensure the  safety of finished 
products,  thanks  mainly  to  our  knowledge  of the  ingredients, 
without resorting to animal testing, after 1 January 1998. However, 
the sec has emphasised the need for exemptions to this rule in the 
case of toxic  effects  caused,  for  example, by  interactions of the 
ingredients. 
c)  Progress  has  however  already  made  it  possible  to  reduce  the 
number of  animals used. 
5.  The Commission has drawn conclusions from these objectives, constraints 
and expected results: 
the Commission has prepared a draft Directive postponing the date 
of 1 January  1998  in  regard  to  ingredients  and  combinations  of 
ingredients. 
The Commission has also decided to pursue its deliberations on presenting 
a  proposal  for  a  European  Parliament and  Council  Directive  amending 
Article  4  ( 1)  (i)  of the  basic  Directive  in  order to  address  the  ban on 
animal testing, notably by regulating the question of  finished products. 
20 PART2 
SCIENTIFIC ASPECTS 
A.  INITIATIVES TAKEN IN 1996 
1.  ECVAM 
Of the  workshops organised and/or published by ECV AM  in  1995  and 
1996 on the development and validation of  alternative tests, those of direct 
interest to the assessment of  consumer safety are as follows: 
Workshop 13. 
Workshop 16 
Workshop 19 
Workshop 24 
Workshop 25 
21 
Methods for Assessing Percutaneous 
Absorption 
Angera, Italy; 30 May-3 June 1994 
Howes et al.  ( 1996)  ATLA 24,  81-
106 
Acute  toxicity  testing  in  vitro  and 
the  classification  and  labelling  of 
chemicals 
Angera, Italy; 18-22 April 1994 
Seibert et al.  ( 1996) A  TLA 24, 499-
510 
Alternative  methods  for  skin 
sensitisation testing 
Angera, Italy; 24-28 April 1995 
de Silva et al. ( 1996) ATLA 24, 683-
705 
The  development  and  validation  of 
expert systems for predicting toxicity 
Angera, Italy; 1-4 October 1996 
Dearden et al.  ( 1997)  A  TLA 24,  in 
press 
Current Status and Future 
Development of  Databases on 
Alternative Methods 
Neublberg,  Germany;  12-15 
September  1996.  Report  m 
preparation. ECV AM has also published in A  TLA recommendations on the application 
of biostatistical methods in the development and validation of alternative 
toxicological methods (A  TLA 24, 511-530, 1996). 
Of the other ECVAM Task Forces, those dealing with Prevalidation, Skin 
Irritation  and  Integrated  Testing  are  also  particularly  relevant  to  the 
cosmetic testing issue. 
In  addition  to  the  ECV AM  validation  studies  on  skin  corrostvlty  and 
phototoxicity, prevalidation studies were begun on modified protocols for 
the  bovine  corneal  capacity  and  permeability  (BCOP)  test  and  the 
fluorescein leakage (FL) test. 
2.  Scientific Committee on Cosmetology (managed by DG XXIV) 
The Alternative Methods/Guidelines Subcommittee of the SCC organised 
three  joint  meetings  with  COLIPNSCAA  T  (15 February  1996, 
19 March 1996, 24 April  1996), a meeting with the Director of ECV  AM 
(6 March 1996) and a meeting designed to draw conclusions and adopt an 
opinion (  6 May 1996), following consultations with DG XXIV .. 
During these meetings the following points were addressed: 
a)  Preparation  of a  discussion  document  on  the ·use  of alternative 
methods  to  animal  studies  in  the  safety  evaluation  of cosmetic 
ingredients or combinations of ingredients. 
b)  Examination  of the  final  report  on  the  EC/HO  study  on  the 
validation of  the Draize eye irritancy test. 
c)  Examination of the  statistical  assessment  data of phase  1 of the 
COLIPA study-validation of  the eye irritancy test in the rabbit. 
d)  Discussion with ECV AM's Unit head on the implementation of the 
provisions  of Article  4  of Directive  93/35/EEC,  involving  a 
general review of  the validation studies. 
e)  Discussions with CO LIP  A/SCAA  T on Industry's approach to  the 
implementation of Directive  93/35/EEC,  which  is  based  on  the 
experience  of the  cosmetic  firms  and  the  outlook  for  replacing 
animal tests. 
3.  DG XII 
Since  1985  the  Commission has  been supporting research in the  field of 
new  in  vitro  alternatives to  animal  experiments  in  pharmaco-toxicology 
applicable to the cosmetic industry. The  BIOTECH  II  programme  launched  after  the  BAP,  BRIDGE  and 
BIOTECH I programmes is also contributing to the development of these 
in-vitro alternatives applicable to cosmetic products. Following the second 
call for  proposals, three projects are being funded with a total budget of 
ECU 3 825 000. 
The projects are: 
•  BI04-CT96-0086: 
New  immuno-pharmaco-toxicological  model:  human 
reconstructed epidennis containing Langerhans cells 
Coordinator:  Dr. Rainer Schmidt 
L'OREAL S.A. 
Centre Charles Zviak 
9a, rue du General Roguet 
F- 92383 Clichy Cedex 
•  BI04-CT96-0036: 
Development  of  in  vitro  systems  using  human 
immortalized cell lines for testing skin irritancy 
Coordinator:  Professor Charles Lapiere 
Laboratory of  Experimental Dennatology 
Universite de Liege 
Tour de Pathologie, B 23 
B - 4000 Liege 
•  BI04-C96-0246: 
4.  COLIPA 
Development for in vitro tests for drug allergenicity and B 
cell switching to IgE synthesis 
Coordinator:  Dr. I. W. Coleman 
Department  of  Pharmacology  & 
Therapeutics 
. New Medical Building 
Ashton Street 
GB - Liverpool L69 3BX 
COLIPA/SCAAT  (the  European  Cosmetic,  Toiletry  and  Perfumery 
Association/ Steering Committee on Alternatives to Animal Testing) 
Following the international two-day scientific symposium organised at the 
end  of 1995,  Scaat  has  continued  its  efforts  towards  getting  validated 
alternative  methods  accepted  and  introduced  into  the  regulatory 
framework. 
On  EYE  IRRITATION,  the  results  of the  COLIPA  validation  study 
became fully available and were submitted for review to  ECV  AM and to 
the  SCC  and DG XXIV.  The relevant working party has drafted a first 
paper  on  the  outcome  of the  study,  which  has  been  accepted  for 
23 publication in Toxicology In  Vitro.  Further statistical analysis of the data 
generated by the study is in progress. 
On SKIN IRRITATION, the specific working party is drafting guidelines 
on human testing of cosmetic ingredients, expected to  be  available early 
1997. This follows the issuing of guidelines on human testing of finished 
products,  issued  in  1995  and  now  published  in  Food  and Chemical 
Toxicology.  Both  guidelines  incorporate  the  need  for  strict  ethical 
standards for such testing. 
On  PERCUTANEOUS  ABSORPTION,  a  working  party  has  been 
collecting  data  generated  by  the  cosmetic  industry  substantiating  the 
validity  of in  vitro  testing,  as  laid  down  in  the  COLIPA  guidelines 
prepared in 1995.  An extensive data package has been made available to 
ECV AM, to OECD, and to the SCC and DG XXIV. 
On PHOTOIRRITATION, a second phase of the EU/COLIPA validation 
study has been successfully completed and discussed with the SCC.  The 
sec has asked for a special study to verify the applicability of the in vitro 
method  for  UV -filters  listed  in  Annex  VII  of the  Cosmetics  Directive. 
This special study will be sponsored by ECV AM and carried out over the 
next year. 
SCAA  T has also created a working party "SKIN SENSITISATION". The 
main  objective  of this  new  group  is  to  define  and ·execute  a  research 
programme on mechanisms, which could pave the way to suitable in vitro 
test methods. 
5.  OECD 
OECD  Guidelines  for  the  Testing  of Chemicals  and  the  Principles  of 
Good Laboratory Practice (GLP) are developed in the broader context of 
the concept of mutual acceptance of data.  Both of these  instruments for 
ensuring harmonized data generation and data quality are an integral part 
of the  1981  OECD Council Decision on the Mutual Acceptance of Data 
(MAD). In accordance with this decision, OECD's 28  Member Countries 
agree  that  data  generated  in  the  testing  of chemicals  in  any  OECD 
Member Country, when in accordance with OECD  Test Guidelines  and 
Principles ofGLP, shall be accepted in any other Member Country for the 
purpose of  assessment and other uses relating to the protection of man and 
the environment.  The  practical consequence of this decision is that data 
developed in a Member Country under these conditions and submitted for 
fulfilling regulatory requirements in another Member Country, cannot an,d 
will  not  be  refused.  Consequently,  OECD Test Guidelines  are  globally 
accepted as the  standard methods for  safety testing and as  such enhance 
the  validity  and  international  acceptance  of test  data.  Recognising  the 
significance  of  OECD  Test  Guidelines,  the  European  Commission 
strongly supports work on the development of new test guidelines and the 
updating of  existing ones. 
24 B.  STATISTICS ON ANIMAL EXPERIMENTS 
On  numerous  occasions  the  Commission  has  urged  the  Member  States,  both 
orally and in writing, to provide the necessary statistics. 
12.2.5.: 
I.  Eight  Member States  reported  that  finished  cosmetic  products  had  not 
been tested on animals on their territory (Italy, Greece, Belgium, Ireland, 
Sweden, Finland, Luxembourg, Germany). 
2.  Six Member States reported that cosmetic ingredients had not been tested 
on animals on their territory (Greece,  the Netherlands,  Ireland.  Sweden, 
Finland, Luxembourg). 
3.  Only  three  Member  States  (Austria,  France,  the  United  Kingdom) 
communicated figures on the number of animals used, while emphasising 
that these figures were not interpretable and that there was uncertainty as 
to what they really signified. In these circumstances the 1995 Report could 
not present comparative tables comprising numerical data, because such a 
table would have given a false picture of  reality. 
4.  As regards the declarations on the absence of tests, it is worth mentioning 
that  certain  Member  States  that  do  not  manufacture  ingredients  will 
certainly be  using  ingredients  tested  in  other Member States or in  third 
countries and that certain ingredients used in cosmetic products may have 
been tested for other purposes. 
Following the final reminder from the Commission in October 1996: 
Ireland and Finland confirmed that cosmetic products had not been tested 
on animals in their countries in  1996.  Sweden did likewise for  1995  but 
reported that in November 1996 it did not have data relating to  1996. 
Portugal reported that cosmetic products were not tested on animals in its 
country. 
Germany confirmed that finished products were not tested on animals and 
that it had no data as regards ingredients testing. 
Finally,  in  the  Netherlands  the  Experiments  on  Animals  Act,  which 
entered into force on 5 February  1997, provides that animal experiments 
may  not  be  carried out with a view to  developing new cosmetics or to 
testing  existing  cosmetics  which  come  within  the  remit  of  the 
Commodities Act. 
The Commission regrets that it does not have more statistics and is  pursuing its 
efforts to obtain them. 
25 C.  STATE OF PROGRESS IN 1996 IN EACH INDIVIDUAL AREA 
1.  Photoirritation/phototoxicity 
ECVAMICOLIPA 
The  biometric  analysis  (=  statistical  evaluation)  of the  data  produced 
during the second validation phase has been completed for the 3T3  NRU 
PI I cell viability test. 
The raw data were imported into an EXCEL file and checked for internal 
consistency.  A  new  mathematical  model  was  developed  to  analyse  the 
complex dose-response relationships. 
The  predictive  value  was  evaluated  by  comparing  the  in  vivo 
photoirritation classification of the materials tested with the classification 
based on the values and biological endpoint of  the in vitro test. 
The variability of the in vitro classification was calculated on the basis of 
the rate of  classification errors. 
The degree of association between the results of the tests conducted by the 
different laboratories was subjected to statistical analysis. 
The  results  of the  biometric  analysis  (dated 29°  March  1996)  indicate 
that the NRU assay is  capable of correctly predicting the irritation 
potential in  man in regard to  most of the  substances tested.  It may  be 
noted that: 
a.  (In many cases) the PIF  does not represent the exactly measured 
values  but estimates which are  below or above the  critical  value 
(>5<) established in phase I of  the validation study. 
b.  The  prediction model  proposed  in  the  SOP  (Standard  Operation 
Procedure)  of  the  3T3  NRU  test  predicts  well  the  in  vivo 
phototoxicity of  most of  the substances tested. 
c.  The  variability  of the  PIF  values  grows  with  the  mcrease  m 
absolute PIF values. 
The number of independent tests in each laboratory was too small 
to authorise a valid estimate of intralaboratory variability data; 
NRU: Neutral red uptake assay", which uses the cells as target and cell toxicity as the outcome. 
26 d.  The  effects  of data  variability  on  the  in  vitro  classification  are 
negligible,  as  the  computer  analysis  of the  classification  errors 
demonstrates. 
The  technical  problems  responsible  for  the  incorrect  classification  of 
certain test materials have been identified and will be taken into account in 
evaluating the performance of  the 3T3 NRU PI test in the final report. 
In particular, one should bear in mind: 
sec 
possible in vivo classification errors 
errors in preparing the solution due to the total lack of information 
on the coded test substances 
the deviations in regard to the SOP. 
Following an SCC recommendation, which emphasised the importance 
of verifying the applicability of the NRU test in evaluating the safety of 
Annex  VII  UV  filters  and  creating  a  database,  a  third  experimental 
phase, directed by ZEBET, and subsidised and coordinated by ECVAM, is 
planned for 1996. The objectives of this study are to test the Annex VII 
UV filters and to prepare an optimised protocol with a view to submitting 
a draft guideline on  in  vitro  photoirritation to  the OECD. The first 
results of  the third phase should be in by September 1997. 
OECD 
The OECD group of national coordinators has decided not to develop the 
in  vivo  method on its  schedule  before  termination of the  third  in  vitro 
validation  phase  at  end  1997.  If the  in  vitro  method  has  not  been 
completed by that date, the OECD will try to develop the in vivo method. 
2.  Percutaneous absorption 
COLIPA 
In  May  1996  a  method  proposed  in  the  ECV AM  workshop  report,  as 
discussed by the industry, ECVAM and OECD secretary, was presented to 
the OECD. 
This  draft,  which  is  currently  being  studied  by  the  OECD  group  of 
national  coordinators,  explicates  the  general  principles  governing  the 
design of protocols  for  skin penetration tests  using  the  excised skin of 
different mammalian species post mortem.  The skin is  excised from  the 
dead animals: 
[- "know-how" regarding the substance tested and choice of  vehicle; 
27 choice of  the type of  cell, receptor fluid, cutaneous membrane and 
control of  membrane integrity; 
potential significance of  the skin metabolism; 
(finite or infinite) dose and duration of  application; 
temperature and humidity conditions; 
sample collection and analysis; 
presentation of  the results and content of  the final report.] 
To support this guideline COLIPA submitted to the OECD, ECV  AM and 
the sec a  dossier consisting of "in-house"  data and  articles  from  the 
literature  designed  to  demonstrate  the  predictive  value,  reliability  and 
robustness of  the in vitro approach. 
It may be summarised as follows: 
•  Predictive value 
The  in  vitro  tests  are  useful  predictors  of in  v1vo  cutaneous 
absorption. 
[Bearing  in mind  the  variability  of in  vivo  data,  there  is  good 
correlation between 
in vitro (pig) and in vivo (rat) data for 1  0+8 hair dyes; 
in vitro (rat) and in vivo (rat) data for 8 coded substances of 
different solubility; 
in vivo (pig) and in vitro (man) data for 7 colouring agents; 
in vitro  (pig)  and in vivo  (man)  data for  1 UV  filter  in 
ethanol solution. 
The skin of  the pig's ear is a very good model of  the human skin in in vitro 
cutaneous absorption tests of  oestradiol.] 
It is possible to design prediction models of skin pharmacokinetics on the 
basis of  in vitro tests. 
[The  in vitro  data in the  rat  can  be  used  in combination  with  a  skin 
phannacokinetic mode. 
The model correctly predicts experimental in vivo measurements in man 
for an ester in suspension in a mixture of  organic solvents and surfactants.] 
•  Reliability 
"In-house"  experience  in  this  domain  pertained  to  different 
categories of cosmetic ingredients, including UV filters, hair dye~. 
sutfactants, mineral hydrocarbons, etc. 
•  Robustness 
28. * 
OECD 
The  dossier  contains  scanty  information  on  the  intra- and 
interlaboratory  variability  of  the  results  and  their  statistical 
analysis. 
[The • skin  penetration  coefficients  (Kp)  and  their  standard 
deviations  give  an  idea  of the  degree  of reproducibility  of the 
results obtained in a series of in  vitro tests conducted on  benzyl 
alcohol.  Good  interlaboratory reproducibility  is  observed  in  one 
study  conducted · in  two  laboratories  using  the  same  in  vitro 
protocol (rat) to measure the skin penetration of  two UV filters.] 
Influence of  operating conditions 
There are  some  articles  in  the  literature that provide  patchy  and 
unsystematic  information on the  influence of storage  conditions, 
the type of  cell used, and the batches of  skin used. 
[- The use of  the excised skin of fresh or deep-frozen pig does 
not influence the results for two UV filters (lipophiles) and 
lactic acid (a hydrophile); 
the  type of cell  used  (static or continuous  flux)  does not 
influence  the  cutaneous  absorption  of  water-soluble 
substances through various types of membranes taken from 
different species  (pig,  rat,  man)  into  different  destination 
solutions; 
the  choice  of  the  destination  solution  is  crucial  for 
substances which have low solubility in water; 
batches of skin taken from three different animals (rats) do 
not  influence  the  data  on  cutaneous  absorption  and 
distribution through the  skin in respect of two  UV  filters 
tested using the same vehicle.] 
The USA and the EU  are at odds about the in vitro approach within the 
OECD's group of  national coordinators. 
At its 7th meeting, held in Paris on 18 and 19 September 1996, the group 
· of national coordinaton decided: 
1.  to  devote a forthcoming workshop to  the study of existing in 
vitro percutaneous absorption data; 
2.  to base the decisions on a guideline document to  be prepared in 
the coming year by the OECD Secretariat on the criteria for the 
validation and acceptance of alternative methods (on the basis 
of  the Solna workshop report); 
3.  to  develop a dual  guideline on in  vivo  and  in  vitro  tests.  in  the 
event of rapid development of  the in vitro dossier. 
sec 
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Although  the  SCC  has  emphasised  that  the  test  protocols  used  by 
industry were not subjected to a formal validation test and although it 
recommended that the existing documentation be  supplemented,  notably 
as  regards intra- and intra-laboratory reproducibility and the  influence of 
the  vehicle  on  the  release  of the  cosmetic  ingredients,  the  sec is 
convinced of the relevance of the in vitro methods and  has  in  recent 
years  agreed  to  draw  on  in  vitro  percutaneous  absorption  data  in  the 
evaluation of  the safety of  several cosmetic ingredients for human use. 
3.  Eye irritation 
ECv:4At//COLIPA 
The  international  EC/HO  validation  study  of  alternatives  to  the 
Draize eye irritancy test did not achieve the expected objectives but it 
inspired the organisation of an ECV  AM/ERGATT workshop on the 
practical aspects of validation and the preparation of a prevalidation 
schedule by ECVAM, as well as the planning of the COLIPA study. 
Limited  results  were  obtained  for  a  small  number  of protocols  in 
COLIPA's first  international validation  phase of alternatives  to  the 
Draize test, where prediction models had been prepared for each test. 
Statistical evaluation of the  results  of the  first  validation phase  indicate 
that the most promising protocols are FLtest2, TEA3  and RBCtest,4 which 
conform reasonably with their prediction models;  however,  for  the  first 
two more reproducibility data is required because in each case they have 
only been used by two large laboratories, while the utility of the  FL  and 
RBC  tests  has  been  challenged  because  the  pertinence  of  their 
classification models is not universally supported.  Moreover,  no  attempt 
has  been made  to  evaluate the  idea of a battery of two  or more  tests to 
replace in vivo assays. 
Currently  there  are  no  validated  alternative  methods  capable  of 
replacing the OECD-405 in vivo eye irritancy test. 
-'·  Skin irritation 
ECVAN! 
Fluorescein leakage test, measures the damage caused to a cell barrier  . 
Tissue Equivalent Assay, measures the time required to cause a 50% reduction in  the viability of 
cells in  reconstituted human skill. 
Red blood cell haemalysis test. used to evaluate damage to the cell membranes. 
30· Folio  wing a prevalidation exercise in  1995 on skin corrosion tests (TER, 
CORROSITEX and SKIN and EPISKIN), ECV  AM undertook a formal 
validation study involving four skin corrosion tests and 60 test materials, 
whose results are expected in 1997. 
Considerable progress has been made in developing a database to predict 
irritation potential.  However the  in  vitro  tests currently being  validated 
concern highly  irritant substances  and  so  this research - which  is  very 
useful  for  classifying  and  labelling  dangerous  substances  - is  only  of 
limited use in evaluating the skin tolerance of  cosmetic ingredients, which 
are  a priori  weakly- or non-irritant substances (at their concentration of 
use). 
There are to  date no validated alternative methodologies capable of 
replacing  the  OECD 404  in  vivo  skin  irritancy test.  An  ECV  AM 
workshop on  human skin equivalents and their uses  is  planned for 
1997. 
OECD 
A  draft  test  strategy  for  determining  the  skin  irritation  potential  of 
chemical  substances  is· on  the  programme  of the  OECD  group  of 
national coordinators. 
The  strategy proposed by the OECD envisages first eliminating the most 
irritant substances through examination of  the structure activity relations 
and structure property relations,  as well as by using information derived 
from in vitro corrosion tests,  before considering recourse to conventional 
tests on rabbits,  in vivo,  or the use of  human volunteers. 
5.  Skin sensitisation 
Identifying  skin  irritation  potential  which  manifests  itself as  contact 
allergy is important in evaluating the safety of  cosmetic ingredients. 
The  impressive  research  work  done  up  to  now  has  helped  clarify  our 
understanding of the mechanistic bases of skin sensitisation. It seems that 
predicting  sensitisation  potential  is  feasible  only  by  combining 
information derived from several supplementary tests. 
ECVAM 
The report of ECV AM workshop  19  reviews  the  situation and  contains 
recommendations  for  research  aimed  at  replacing  current  animal  tests, 
viz.: 
•  refine  the  DEREK  expert  system  identifying  the 
structural  alerts  of skin  sensitisation  and  develop 
supplementary  systems  based  on  the  SARs 
(Structure Activity Relationships) 
31 • 
• 
• 
• 
standardise  the  tests  "on  cultures"  of the  most 
promising  in  vitro  cells,  and  notably  study  the 
essential  role  of mediators  derived  from  human 
dendritic  cells  and  standardise  the  methods  of 
isolating and cultivating these cells 
develop  other  in  vitro  models,  notably  on  skin 
explants 
develop an in vitro skin metabolism system 
develop an adequate database on the  basis of these 
tests, through a validation exercise using a suitable 
in vivo ·database. 
ECVAM  hopes  to  support a  prevalidation  study  on an  in  vitro  test,  in 
1997. 
Bearing in mind the complexity of  the process and the fact that predicting 
sensitising  potential  is  a  difficult  task  because  of the  variability  of 
individual response, definitive results in this domain can be expected 
only in the medium term, if not indeed the long term. 
·  6.  Skin compatibility of the finished product 
The guidelines prepared by COLIPA in November 1995 on evaluating the 
skin  compatibility  of  flnish~d·  cosm~tic products  in  the  framework  of 
strictly  controlled  clinical  studies,  which  were  informed  by  ethical 
considerations  and  based  on  prior  knowledge  of the  composition  and . 
stability of the  tested  products  and  prior evaluation of the  toxicity  data 
pertaining to the ingredients used in the product, have been published in 
Food and Chemical Toxicology [34 (1996) 651-660].  , 
.. ., 
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